Phase III LEAP-006 safety run-in (Part 1): 1L pembrolizumab (Pembro) + chemotherapy (Chemo) with lenvatinib (Len) for metastatic NSCLC
Nishio M, Peled N, Zer A, Houghton B, Bar J, Drew D, Herbst R, Rodriguez-Abreu D, Talpur R, Golden L, Yin L, Dang T, Hui R. Phase III LEAP-006 safety run-in (Part 1): 1L pembrolizumab (Pembro) + chemotherapy (Chemo) with lenvatinib (Len) for metastatic NSCLC. Annals Of Oncology 2020, 31: s848-s849. DOI: 10.1016/j.annonc.2020.08.1627.Peer-Reviewed Original ResearchMetastatic NSCLCSafety run